Moderna (MRNA) Operating Expenses: 2017-2025
Historic Operating Expenses for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $1.3 billion.
- Moderna's Operating Expenses fell 33.95% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 26.74%. This contributed to the annual value of $7.2 billion for FY2024, which is 35.23% down from last year.
- Latest data reveals that Moderna reported Operating Expenses of $1.3 billion as of Q3 2025, which was up 21.64% from $1.0 billion recorded in Q2 2025.
- Over the past 5 years, Moderna's Operating Expenses peaked at $3.8 billion during Q3 2023, and registered a low of $671.0 million during Q1 2021.
- In the last 3 years, Moderna's Operating Expenses had a median value of $1.9 billion in 2024 and averaged $2.0 billion.
- Its Operating Expenses has fluctuated over the past 5 years, first surged by 583.60% in 2021, then tumbled by 49.73% in 2024.
- Quarterly analysis of 5 years shows Moderna's Operating Expenses stood at $1.8 billion in 2021, then skyrocketed by 94.56% to $3.5 billion in 2022, then fell by 19.95% to $2.8 billion in 2023, then dropped by 21.14% to $2.2 billion in 2024, then plummeted by 33.95% to $1.3 billion in 2025.
- Its Operating Expenses stands at $1.3 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $1.2 billion for Q1 2025.